top of page
Backgrounds.jpg

The voice of Colville and northeastern Washington since 1896

|

September 15, 2026

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Compass Therapeutics, Inc. - Common Stock (NQ:CMPX)

0.8639 -0.0372 (-4.13%)
Delayed Quote Updated: 3:46 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Compass Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Which stocks are experiencing notable movement on Tuesday? ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
Gapping stocks in Tuesday's session ↗
Via Chartmill
News headline image
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win ↗
Compass Therapeutics (NASDAQ:CMPX) Chief Executive Officer Tom Schuetz said the company is preparing for a key U.S. Food and Drug Administration meeting on tovecimig, its DLL4/VEGF bispecific antibody,... 
Via MarketBeat
On Wednesday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
Monday's session: most active stocks ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
Top movers in Monday's pre-market session ↗
Via Chartmill
Top movers in Friday's after hours session ↗
Via Chartmill
News headline image
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch ↗
This clinical-stage biotech develops immunology therapies for autoimmune and inflammatory diseases, with a diverse pipeline underway. 
Via The Motley Fool
News headline image
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗
This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and immunotherapy markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Compass Therapeutics Inc (NASDAQ:CMPX) Reports Wider Q2 2025 Loss, Shares Show Mixed Reaction Amid Clinical Progress ↗
Compass Therapeutics reports Q2 2025 results with a wider-than-expected loss but shows progress in clinical trials for oncology treatments. Market reacts mixedly. 
Via Chartmill
News headline image
Compass Therapeutics Posts Wider Q2 Loss ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Top movers in Wednesday's session ↗
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer ↗
Compass Therapeutics' Phase 2/3 trial shows tovecimig plus paclitaxel significantly improves response rates in advanced biliary tract cancer patients. 
Via Benzinga
News headline image
Earnings Scheduled For August 11, 2025 ↗
 
Via Benzinga
News headline image
What's going on in today's after hours session ↗
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Top 3 High-Momentum Companies Analysts Are Still Bullish On
Momentum investors seek to take advantage of share price rallies to buy companies before they peak; analysts think these three firms still have room to grow. 
Via MarketBeat
News headline image
CMPX Stock Earnings: Compass Therapeutics Meets EPS for Q2 2024 ↗
CMPX stock results show that Compass Therapeutics met analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
CMPX Stock Earnings: Compass Therapeutics Beats EPS for Q1 2024 ↗
CMPX stock results show that Compass Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
3 Penny Stocks With the Power to 10X Your $1K Investment ↗
The 10X penny stocks discussed here are a much more reliable investment than many other alternatives investors are likely to encounter. 
Via InvestorPlace
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page